Trachoma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) No edit summary |
m (Changes made per Mahshid's request) |
||
| Line 17: | Line 17: | ||
[[Category:Neglected diseases]] | [[Category:Neglected diseases]] | ||
[[Category:Tropical disease]] | [[Category:Tropical disease]] | ||
[[Category:Primary care]] | [[Category:Primary care]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 18:59, 18 September 2017
|
Trachoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Trachoma cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Trachoma cost-effectiveness of therapy |
|
Risk calculators and risk factors for Trachoma cost-effectiveness of therapy |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year.